Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome.

@article{Mack2011BypassVD,
  title={Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome.},
  author={Michael J. Mack and Adrian P. Banning and Patrick Washington Serruys and Marie-claude Morice and Yves Taeymans and Guido van Nooten and Gianfederico Possati and Filippo Crea and Kristin L. Hood and Katrin Leadley and Keith D. Dawkins and Arie Pieter Kappetein},
  journal={The Annals of thoracic surgery},
  year={2011},
  volume={92 6},
  pages={2140-6}
}
BACKGROUND Diabetes mellitus increases adverse outcomes after coronary revascularization; however, the impact of metabolic syndrome is unclear. We examined the impact of diabetes and metabolic syndrome on coronary artery bypass graft surgery (CABG) and stenting outcomes to determine the optimal revascularization option for the treatment of complex coronary… CONTINUE READING